Morningstar - Sociedad Quimica y Minera de Chile S.A. Series B ADS (QYM) SQM Shares Look Compelling Following Sell-Off Despite Our Reduced Near-Term Expectations

Report

Morningstar

Seth Goldstein

EUR 100.00 For Business Accounts Only

SQM Shares Look Compelling Following Sell-Off Despite Our Reduced Near-Term Expectations

SQM reported detailed first-quarter results that were in line with our expectations as lithium prices fell 11% year on year to roughly $14,600 per metric ton. The company previously reported high-level results on April 26 following the annual shareholders meeting. However, in addition to the financial results, management guided to lithium prices falling to $11,000 to $12,000 per metric ton in the second half of 2019, which is slightly below our expectations for 2019 but is in line with our 2020 ...

23/05/2019 17 EN

Underlying

Sociedad Quimica y Minera de Chile S.A. Series B ADS

See profile

US8336351056 Berlin Stock Exchange Chile

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Seth Goldstein

Other Reports on these Companies

Vermilion Research

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

EUR 45.90

September 22, 2023 September 22, 2023 1 EN

TheScreener

With a more favourable environment, SOCIED.QM.Y MIDC.SA improves to Slightly Positive

SOCIED.QM.Y MIDC.SA (US), a company active in the Commodity Chemicals industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date March 15, 2022, the closing price was USD 70.81 and its potential was estimated at USD 79.25.

Free Trial

March 16, 2022 March 16, 2022 1 EN

Vermilion Research

Vermilion Compass: Weekly Equity Strategy

Volatility & Consolidation Continues Our key "lines in the sand" were tested last week, including 4257 on the S&P 500, $334 on the Nasdaq 100 (QQQ), 33,250 on the Dow Jones Industrial Average, and $102.50 on the S&P 600 Small Caps (IJR). After a brief dip below these levels, buyers immediately stepped up and reclaimed these supports. It was a clear win for the bulls (for now), and we are constructive as long as we are above these levels. Moving forward we continue to expect more volatility and consolidation between 4257 and 4590-4595 on the S&P 500, and between $334 and $367 on the Nasdaq 100...

EUR 45.90

March 1, 2022 March 1, 2022 1 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

SQM Shares Look Compelling Following Sell-Off Despite Our Reduced Near-Term Expectations

Vermilion Short Shots: Technically Vulnerable Stocks

With a more favourable environment, SOCIED.QM.Y MIDC.SA improves to Slightly Positive

Vermilion Compass: Weekly Equity Strategy

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe